311 results about "Th polarization" patented technology

The invention provides a tumor immunotherapy curative effect prediction system based on polarization characteristics of neutrophil, and relates to the technical field of biology, the system comprises a neutrophil detection module used for determining neutrophil information; the patient information module is used for acquiring tumor information and immune information of a patient; the immunotherapy scheme information module is used for acquiring immunotherapy scheme information of the patient; the historical data acquisition module is used for acquiring historical patient information; the immune state coefficient module is used for determining the immune state coefficient of the patient; the prediction model module is used for obtaining the predicted tumor size through the trained tumor size prediction model; the immune state prediction module is used for determining a predicted immune state coefficient; and the curative effect prediction module is used for determining a predicted tumor immunotherapy curative effect score. According to the invention, the predicted tumor immunotherapy curative effect can be evaluated according to two aspects of predicting the tumor size and predicting the immune state coefficient.

The invention provides a nano photosensitizer modified by outer membrane vesicles of genetically engineered bacteria as well as a preparation method and application of the nano photosensitizer. The nano photosensitizer is a nano material with the particle size of 80-120 nm, and the nano photosensitizer modified by the genetically engineered bacterium outer membrane vesicle comprises dipalmitic acid phosphatidylcholine (DPPC), distearoyl phosphatidylcholine (DSPC), dioleoyl lecithin (DOPC), cholesterol, a small molecule dye and CD47nb-OMV membrane protein. The chemical structure of the small molecule dye is shown as a formula I or a formula II. The nano photosensitizer OBDlp modified by outer membrane vesicles of genetically engineered bacteria serves as a novel nano photosensitizer, tumor targeting PTT is mediated through NIR II FL / PA imaging, tumor immunogenicity is improved, antigen presenting cells are activated, and infiltration and functionalization of CD8 + T cells are caused. And OBDlp and laser are combined to induce release of a large amount of DAMPs and trigger ICD to promote maturation of cDC1s. Meanwhile, a CD47 nano antibody carried by the nano photosensitizer induces polarization of M1 phenotype macrophages by blocking a CD47-SIRP alpha signal transduction axis, and an immunosuppression tumor microenvironment is reversed.

The invention discloses a PEI and targeting peptide modified magnetic nano-carrier and a preparation method and application thereof. The nano-carrier is regular in morphology and uniform in particle size and has good crystallinity and magnetic performance. E5 polypeptide and RGD cyclic peptide on the surface of the nano-carrier are respectively combined with CXCR4 protein and integrin on the surface of a tumor cell, and the nano-carrier and CXCR4 are internalized into lysosome through an integrin-mediated way, so that the target protein CXCR4 is degraded. The PEI in the nano-carrier can load and deliver siRNA into tumor cells to silence the expression of CXCR4 mRNA (messenger Ribonucleic Acid). Through nucleic acid delivery and a protein targeted degradation strategy, the CXCR4 level of tumor cells is jointly reduced, the migration ability of the tumor cells is inhibited, and meanwhile, the anti-tumor effect of M1 type polarization of macrophages is activated.

The invention discloses an application of NRP1 in prevention and treatment of acute anterior uveitis. Researches find that expression deletion of the NRP1 promotes polarization of macrophages to M1, expression of the NRP1 in an iris-ciliary body compound of an acute anterior uveitis model mouse is reduced, an inhibitor of the NRP1 promotes the inflammation phenotype of the acute anterior uveitis model mouse, the NRP1 protein inhibits the phenotype of the acute anterior uveitis model mouse, and the NRP1 protein inhibits the inflammation phenotype of the acute anterior uveitis model mouse. The expression deletion of the NRP1 in the macrophages aggravates the inflammation phenotype of an acute anterior uveitis model mouse, so that the NRP1 can be used for preventing and / or treating the acute anterior uveitis and has a very good application prospect.

A fibroblast activation protein (FAP) targeting chimeric antigen receptor macrophage and its construction method and application. The expression of FAP increases in senescent cells of various senescent diseases. Immune cells, especially macrophages, specifically eliminates senescent cells after expressing chimeric antigen receptor recognizing FAP protein, thereby reducing the pathogenic effect of senescent cells. Macrophages expressing the FAP chimeric antigen receptor can undergo M2-type polarization, which do not produce inflammatory factors to deteriorate age related diseases, have good infiltration ability to tissues with dense matrix, do not induce graft-versus-host disease and have high recognition efficiency of senescent cells and good phagocytic effect. This provides a new idea for preparing reagents for eliminating senescent cells, which have wide potential in practical application.

The invention relates to the technical field of medicines, in particular to a construction method and application of a photothermal conversion platform for treating osteoarthritis by regulating synovial macrophage polarization. According to the present invention, the M2 membrane-structured black phosphorus selenium carbon body (M2-BPSeC) photo-thermal nano-platform is innovatively provided, the triple functions of bionic targeting delivery, precise thermal control intervention and immune microenvironment remodeling are integrated, and the excellent synergistic treatment effect is represented in the in-vitro cell model and the OA animal model. The technology breaks through the technical bottleneck that traditional treatment is insufficient in targeting and single in intervention dimension, precise functional coupling of the physical thermal effect and immunoregulation is achieved for the first time, and a brand new strategy of targeting-temperature control-immunity integration is provided for osteoarthritis treatment. The efficient and controllable preparation process and the remarkable multi-dimensional treatment effect open up a new path for cartilage regeneration and immune balance regulation and control.

The invention discloses an alveolar macrophage glycyrrhetinic acid liposome and a preparation method thereof, and belongs to the field of biological medicines. The surface of glycyrrhetinic acid lipidosome is modified with alveolar macrophage targeting molecules, so that the lipidosome can specifically target M1 alveolar macrophages induced by lipopolysaccharide serving as a main component of the outer wall of gram-negative bacteria, entrapped glycyrrhetinic acid is ingested by the alveolar macrophages, M2 polarization is specifically induced, and the specific targeting effect is achieved. Lung inflammatory injury caused by gram-negative bacteria is reduced, lung tissue injury and fibrosis caused by excessive inflammation are prevented, and great significance is achieved for pneumonia caused by gram-negative bacteria.

The invention discloses an application of a small molecular compound LZ-A4 in preparation of a preparation or a medicine for treating malignant tumors. The chemical formula of the small molecule compound LZ-A4 is C19H11Cl2N3O3S, and the small molecule compound LZ-A4 can promote degradation of LGMN in malignant tumor cells, inhibit proliferation of tumor cells and inhibit polarization of macrophages to M2 type. The research on a colorectal cancer mouse transplantation tumor model proves that the development of the colorectal cancer can be effectively inhibited by single treatment of the LZ-A4, and the volume of the tumor can be further reduced after the LZ-A4 is combined with a clinical first-line chemotherapeutic drug Oxaliplatin for the colorectal cancer. Meanwhile, the LZ-A4 can inhibit M2 type polarization of macrophages in a tumor microenvironment in vivo, promote infiltration of cytotoxic T cells, remodel the tumor microenvironment and activate anti-tumor immunity. In addition, the A4 has good toxic and side effects, and does not cause further reduction of the body weight of the mouse after being combined with chemotherapeutic drugs.

The invention relates to the field of biological medicine, in particular to application of a reagent for measuring or regulating the expression level of HIF-1alpha in preparation of a kit for diagnosing or gout, the kit containing the reagent and a gout prediction device. The HIF-1alpha is applied as a gout diagnosis target and a treatment target for the first time, the polarization degree of Th17 cells in an inflammatory microenvironment of a gout patient can be specifically reflected, early dynamic monitoring of gout related inflammatory activities is achieved, polarization of Th17 cells and expression of related proinflammatory factors are inhibited in a targeted mode, and a new strategy is provided for prediction, diagnosis and treatment of gout.

The invention relates to the field of chemical analysis, and particularly discloses a method for detecting indole and derivatives thereof in serum and excrement. Before liquid chromatography-mass spectrometry detection, a methanol-water mixed solvent is adopted for extraction, and freeze grinding, ultrasonic treatment, standing, centrifugation and other steps are carried out. According to the pretreatment process, the influences of complex matrixes and more interfering substances are eliminated, more tryptophan metabolites are detected at the same time, the adopted pretreatment mode is simple, low in cost and environmentally friendly, and qualitative and quantitative detection of indole and derivatives thereof in complex biological samples can be achieved. The indole derivative has important significance in the fields of enhancing the integrity of the intestinal epithelial barrier, inhibiting neuroinflammation, improving insulin resistance and regulating and controlling the polarization direction of immune cells based on deep research of indole and the indole derivative.

The invention discloses an engineered macrophage and a pharmaceutical composition and application thereof, and CCM3 expression in the engineered macrophage is inhibited, so that the engineered macrophage is polarized towards the M2 direction or the engineered macrophage is an M2 type macrophage. Besides, the invention further develops a temperature-sensitive cell-loaded hydrogel preparation which can promote polarization of macrophages in the M2 direction by inhibiting expression of signal molecules CCM3 on adhesion spots, and the temperature-sensitive cell-loaded hydrogel preparation can promote bone defect immune osteogenesis through local injection.

The present invention discloses a lactoferrin composition and its application for improving immunity by regulating macrophage immune activity, and belongs to the technical field of functional compositions. The present invention obtains a lactoferrin composition with regulating macrophage immune activity by compounding lactoferrin, α-lactalbumin, N-acetylneuraminic acid and yeast β-glucan in a specific ratio, the raw material of the composition is easy to obtain, and four components work together to significantly enhance its phagocytic activity without changing the activity of macrophages, regulate the polarization state of macrophages in inflammatory response, inhibit macrophages from polarizing to pro-inflammatory M1 type, and promote macrophages to polarize to anti-inflammatory M2 type; At the same time, the composition can also enhance the antigen presentation ability of macrophages and the activation of immune T cells, and improve body immunity. Therefore, the composition provided by the present invention can be used to prepare health products, food or medicines, etc. that improve immunity.

The invention belongs to the technical field of immunology, and particularly discloses an in-vitro preparation method and application of an induced follicular regulatory T cell iTfr.The in-vitro preparation method comprises the steps that mouse spleen single-cell suspension or healthy human peripheral blood is obtained, peripheral blood mononuclear cells are obtained, then initial CD4 + T cells are obtained through immunomagnetic bead sorting, and iTfr cells are obtained; then carrying out induced differentiation by using an antibody and a specific cytokine, and carrying out continuous stimulation and culture by adopting two different cytokine polarization conditions, so as to obtain the iTfr cell. The invention provides a method for preparing the iTfr cells in vitro, which is expected to obtain an enough number of induced follicular regulatory T cells, and provides an important tool and a treatment means for in vitro research of immune tolerance related diseases such as autoimmune diseases and organ transplantation.

The invention relates to a lung cancer organoid and peripheral blood source immune cell co-culture model and a construction method thereof. Specifically, the invention provides a construction method of a macrophage and tumor organoid co-culture model for evaluating anti-tumor activity, monocytes of autologous or allogeneic peripheral blood of a patient are induced and differentiated into high-purity macrophages in vitro, and the high-purity macrophages and lung cancer tumor organoid are subjected to three-dimensional co-culture in matrigel; the model aims at highly reducing a core interaction network of tumor cells and macrophages in TME; the dynamic change of the polarization state of the macrophage is simulated and observed; the problem that an organ-like model is incomplete due to immune component deficiency or spatial positioning distortion of an existing model is effectively solved, an experimental platform closer to the physiological state is provided for tumor immune microenvironment research, and therefore development of the tumor immune treatment field is promoted.

The invention belongs to the technical field of biological detection, and provides a multiple cell factor detection kit in macrophage polarization and a preparation method and application thereof, and the detection kit comprises a capture antibody, a detection antibody, a mixed protein standard substance, a diluent and a washing buffer solution. The capture system is used for preparing a capture antibody coupled with a fluorescence coding microsphere by coupling a biotinylated antibody with a fluorescence microsphere coated with biotin, and the detection system is used for preparing a fluorescence labeled antibody by coupling derivatized phycoerythrin PE-SMCC with a specific thioether bond of a sulfhydrylated antibody. The mixed protein standard substance adopts a freeze-drying protection system containing BSA, trehalose and the like. The single hole of the kit can synchronously detect multiple cell factors, the sample dosage is only 25 microliters, the kit is suitable for in-vitro tests of mouse mononuclear macrophage leukemia cell lines RAW264.7, compared with a traditional ELISA method, the efficiency is improved by 10 times, the cost is reduced, and the kit has the remarkable advantages of being high in throughput, wide in linear range and high in stability.

A method to obtain more effective CAR-T cells, which are FOXO1 inhibited. The inhibition of FOXO1 potentiates the ability to induce lysis of a target cell thanks to the increased expression of TNF-α and other inflammatory cytokines, induces spontaneous cell polarization comparable to that obtained by stimulation with chemokines and thus improves the motility of the cells, induces a sharp increase of memory T cells and allows to obtain more efficient CAR-T cells to treat solid tumors than classical CAR-T cells obtained with the known protocol. An 10 ex vivo method to obtain improved CAR-T cells including the steps of (i) cultivate T cells obtained from a subject with a FOXO1 inhibitor during a time of 2 to 10 days; (ii) transducing (or transforming) the T cells into CAR-T cells thanks to a known method.

The invention belongs to the technical field of medicines, and particularly relates to application of a xanthohumol substance in preparation of a microglial cell selective polarization preparation, the xanthohumol substance is xanthohumol or a xanthohumol derivative, and microglial cells are selectively polarized to M2 type. Experiments prove that when PolyI: C induces activation of microglial cells, expression of M2 type microglial cell surface markers YM is reduced, while after the microglial cells are subjected to xanthohumol pretreatment and then subjected to PolyI: C stimulation, activation of the microglial cells induced by PolyI: C is reduced, expression of the M2 type microglial cell surface markers YM is increased, activation of the microglial cells induced by PolyI: C is reduced, and activation of the microglial cells induced by PolyI: C is reduced. Therefore, Xn can inhibit inflammatory response by adjusting activated microglial cells to be polarized to M2.

The invention relates to the technical field of medicines, in particular to application of a mesenchymal stem cell exosome in preparation of a thermoplegia neuroprotective agent. It is found through experiments that MSC-Exos can remarkably promote polarization conversion of microglial cells from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype, and therefore damage, caused by heat stroke, to a central nervous system is relieved.

The invention relates to the technical field of medical chemistry and tumor treatment, in particular to application of a novel NOX4 inhibitor ZZU026 and derivatives thereof in tumor resistance and immune response change. The preparation method of the ZZU026 comprises the following steps: replacing N, N-dimethylamino on a benzene ring of GKT137831 with morpholinyl; methoxyl is introduced into the core skeleton. The ZZU026 has a remarkable inhibiting effect on NOX4, has the functions of inhibiting tumor growth, new vascularization and immune-related diseases, regulating and controlling polarization of macrophages and the like, and can inhibit phenotype transformation of macrophages from M1 to M2 and finally inhibit proliferation and immune escape of lung cancer cells; the ZZU026 and the derivatives thereof can be prepared into drugs, health care products, tablets, particles, capsules, oral liquid or injection, and can be used for treating lung cancer and other tumors.

The invention discloses application of a mast cell polarization typing detection kit, and belongs to the field of biological medicine. The kit comprises a mast cell characteristic enzyme TPSB2 detection reagent, and one or more of a mast cell MC1 type polarization detection reagent and a mast cell MC2 type polarization detection reagent, the MC1 type polarization is CCL27, and the expression of TNF-alpha is up-regulated; and the MC2 type polarization comprises expression up-regulation of CCL3, IL-16 and VEGFA (vascular endothelial growth factor A). Mstoma cells have dual effects in a tumor microenvironment, can promote tumor progression, and also can enhance anti-tumor immune response. The mastocyte polarization typing is identified through the expression level of the biomarker, so that the mastocyte polarization typing can be rapidly and accurately evaluated, identification indexes and tools are provided for further discussing the functions of mastocytes in different polarization states, cancer diagnosis can be assisted, the onset risk of cancer can be reduced, and the method is suitable for popularization and application. And an immunotherapy target is provided for clinical treatment of cancers.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an FXR agonist combined with a PD1 / PD-L1 monoclonal antibody in preparation of an anti-liver cancer medicine, in particular to application of obeticholic acid (OCA) combined with a Czodiasumab in treatment of liver cancer. The invention also provides an application of the nuclear receptors FXR and PD1 in liver cancer treatment, specifically, the nuclear receptors FXR and PD1 are taken as double targets, and the medicine for treating liver cancer is obtained. An FXR agonist OCA is used for activating FXR, and it is found that activation of FXR can regulate immune infiltration of T cells by promoting polarization of macrophage M1, so that growth of tumors is inhibited. In addition, expression of PD-L1 in liver cancer can be promoted by activating FXR, and a better tumor inhibition effect can be achieved by combining an FXR agonist OCA with a PD1 monoclonal antibody for immunotherapy.

The invention discloses an immunomodulatory composition based on a cordycepin-selenium nano chelate and a preparation method thereof, and belongs to the technical field of biological medicines.The immunomodulatory composition is characterized in that 15-25 nm zero-valent selenium nano particles are chelated through hydroxyl of cordycepin and N7 site bidentate coordination, and a stable five-membered ring structure with the molar ratio is formed; the preparation method comprises the following steps: reducing sodium selenite in an inert atmosphere to generate selenium colloid, chelating the selenium colloid with a cordycepin ethanol solution, and carrying out ultrafiltration and freeze-drying to obtain the product. The invention aims to solve the problems of fuzzy structure, inconsistent batch, uncontrollable immunomodulatory function and the like caused by non-specific mixing in the prior art, and the composition can bidirectionally regulate and control IRF3 pathways, promote polarization of M2 type macrophages and proliferation of Treg cells, and has a clear immunomodulatory mechanism and excellent stability.

The application discloses a kind of nanoparticles for tumor sonodynamic combined individualized immunotherapy and its preparation method and application, belong to the field of biological medicine.The nanoparticles for tumor sonodynamic combined individualized immunotherapy are double-shell core structure nanoparticles formed by inner core and shell, and the inner core is formed by self-assembly of TLR3 agonist Poly (I:C), L-arginine and polylysine, and the shell is hyaluronic acid layer HA-Ce6 conjugated with photosensitizer Ce6.It is found through experiment verification that the nanoparticles can target tumor, generate reactive oxygen species to kill tumor cells under the action of ultrasound, promote M1 macrophage polarization and produce NO release at the same time, play the role of antitumor and immune effect, and realize the combined application of sonodynamic and NO gas therapy.The nanoparticles for tumor sonodynamic combined individualized immunotherapy can trigger systemic immune response, inhibit primary tumor, produce immune memory effect, and prevent tumor metastasis and recurrence.

The invention relates to the technical field of biology, in particular to a preparation method and application of a bionic nano regulator. The invention provides a bionic nano regulator. The nano regulator comprises a therapeutic drug; the therapeutic drug is prepared from Ce6 and SB525334. And extruding the bacterial outer membrane vesicles and the PLGA encapsulating the Ce6 and SB525334 medicines to obtain the bionic nano regulator. Under photodynamic therapy, the bionic nano regulator can be recognized, taken and delivered to tumor tissues by neutrophils. The bionic nano regulator can regulate and control polarization of neutrophil to an anti-tumor N1 type, promote the neutrophil to release neutrophil elastase, specifically kill tumor cells and reverse a tumor immunosuppression microenvironment. Under the combined treatment of photodynamic-immunotherapy, the biomimetic nano regulator obviously inhibits tumor growth and enhances the anti-tumor immune response of the body.

The present invention relates to a method of producing macrophages. The macrophages are produced from monocytes harvested from a subject by incubating said monocytes in a medium comprising a Colony Stimulating Factor 1 Receptor (CSF-1R) agonist. Before monocytes are harvested, the subject is treated with G-CSF. The macrophages produced by the method are capable of being polarised to a pro-restorative, anti-inflammatory and / or anti-fibrotic phenotype. The invention also relates to methods of treating inflammatory diseases comprising administering the macrophages produced by the method to a subject.

An object of the present invention is to provide a method for preventing or treating myopia, and a composition used in said method. The present invention provides a method and composition for inhibiting, improving, or treating myopia by administering a substance that induces M2 macrophage polarization, a substance that regulates the function of choroid-resident immune cells, such as a mast cell stabilizer or a chemical mediator release inhibitor, or lactic acid bacteria. Regulating the function of choroid-resident immune cells, for example by inducing the polarization of M2 macrophages in the choroid or by administering a mast cell stabilizer, a chemical mediator release inhibitor, or lactic acid bacteria, is effective in myopia prevention and treatment.

The invention discloses a vaccine based on a protein CAMKII binding domain as well as a preparation method and application of the vaccine. The vaccine based on the protein CAMKII binding domain is a recombinant protein and comprises a CaMKII binding domain protein and an antigen epitope, and the sequence of the CaMKII binding domain protein is as shown in SEQ ID NO. 1. The CaMKII binding domain protein is connected with the nucleotide sequence of the antigen epitope in a gene fusion mode, the recombinant protein is obtained through expression by means of molecular biology, the obtained recombinant protein effectively promotes polarization of macrophages into M1 phenotype and releases more inflammatory cytokines IL-6 to be combined with the antigen epitope, the effect that the antigen is presented by BMDCs is remarkably improved, and the recombinant protein can be applied to the preparation of the antigen. The tumor vaccine provided by the invention has a good application prospect, and can prevent and / or treat cancers.

The present invention discloses the application of the PPP1R3B gene in the preparation of atherosclerotic detection reagents or therapeutic drugs. The present invention for the first time discovers that the PPP1R3B gene is a reliable target for the diagnosis and treatment of atherosclerosis. By exogenous up-regulation of the expression of PPP1R3B, inducing the polarization of M2-type MΦ macrophages, it can alleviate the plaque inflammatory microenvironment, promote glycolipid metabolic reprogramming, support the energy load required by cells, delay the progression of atherosclerotic plaques, improve the quality of life of cardiovascular disease patients, reduce the incidence of cardiovascular and cerebrovascular events, and can be applied to the preparation of atherosclerotic diagnostic reagents and therapeutic drugs.

The present invention discloses a tumor immune microenvironment-regulated light-activated ferroptosis nanoparticle, a preparation method, and an application thereof, relating to the field of biomedicine technology. The preparation method comprises the following steps: dissolving albumin and ferritin in water, adjusting the pH to alkaline, adding a photosensitizer and lipoic acid, mixing, then adding a solvent, performing a mixing reaction, then adding a cross-linking agent, continuing the reaction, and then centrifuging and drying to obtain the tumor immune microenvironment-regulated light-activated ferroptosis nanoparticle. The tumor immune microenvironment-regulated light-activated ferroptosis nanoparticle reverses the tumor immunosuppressive microenvironment by inducing ferroptosis of tumor cells, activating dendritic cells, and regulating the M1 polarization of M2 tumor-associated macrophages, thereby enhancing the effect of tumor immunotherapy.

The invention belongs to the field of biological medicine, and particularly relates to application of soluble B7-H5 in preparation of a Crohn disease detection reagent. According to the invention, the level of soluble B7-H5 (sB7-H5) in serum of a patient suffering from Crohn's disease (CD) is deeply analyzed by using an ELISA (Enzyme-Linked Immunosorbent Assay) technology. Studies find that sB7-H5 in serum of a CD patient is remarkably and highly expressed and is positively correlated with a disease activity index (CDAI). Further experimental verification shows that blocking of B7-H5 can promote polarization of inflammatory macrophages. Based on the discoveries, the invention provides the application of the serum B7-H5 as the molecular marker of the Crohn's disease to development of products for detection, prognosis or treatment of the Crohn's disease. The molecular marker can be in a soluble B7-H5 gene or protein form. The invention also shows that the B7-H5 can be used as a potential target for developing the medicine for preventing and treating the Crohn disease, and has important clinical application value.